Antitumor activity of lenvatinib mesilate in human hepatocellular carcinoma preclinical models

被引：0
|
作者：
Matsuki, Masahiro
Yamamoto, Yuji
Hoshi, Taisuke
Kimura, Takayuki
Funahashi, Yasuhiro
Matsui, Junji
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1805
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1805
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells
    Augello, Giuseppa
    Modica, Martina
    Azzolina, Antonina
    Puleio, Roberto
    Cassata, Giovanni
    Emma, Maria Rita
    Di Sano, Caterina
    Cusimano, Antonella
    Montalto, Giuseppe
    Cervello, Melchiorre
    CELL DEATH & DISEASE, 2018, 9
  • [32] Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro
    Wang, Xinyue
    Qian, Songyi
    Wang, Siyi
    Jia, Sheng
    Zheng, Nishang
    Yao, Qing
    Gao, Jian
    PEERJ, 2023, 11
  • [33] Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma
    Ryo Ito
    Koji Miyanishi
    Tomohiro Kubo
    Kota Hamaguchi
    Takahiro Osuga
    Shingo Tanaka
    Hiroyuki Ohnuma
    Kazuyuki Murase
    Kohichi Takada
    Minoru Nagayama
    Yasutoshi Kimura
    Toru Mizuguchi
    Ichiro Takemasa
    Junji Kato
    Hepatology International, 2023, 17 : 735 - 744
  • [34] Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway
    Hao, Jianwen
    Peng, Qizhen
    Wang, Keruo
    Yu, Ge
    Pan, Yi
    Du, Xiaoling
    Hu, Na
    Zhang, Xuening
    Qin, Yu
    Li, Huikai
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [35] Antitumor activity of sorafenib in osteosarcoma (OS) preclinical models
    Pignochino, Y.
    Grignani, G.
    Cavalloni, G.
    Motta, M.
    Bruno, S.
    Camussi, G.
    Ferrari, S.
    Picci, P.
    Berger, M.
    Aglietta, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] The antitumor activity of lenvatinib (LEN) in combination with everolimus (EVE) in human renal cell carcinoma (RCC) xenograft models is dependent on VEGFR and FGFR signaling
    Kimura, T.
    Adachi, Y.
    Matsuki, M.
    Yamaguchi, A.
    Ozawa, Y.
    Okamoto, K.
    Mitsuhashi, K.
    Hoshi, T.
    Tohyama, O.
    Tai, K.
    Ogo, M.
    Matsui, J.
    Funahashi, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
    Matsuki, Masahiro
    Hoshi, Taisuke
    Yamamoto, Yuji
    Ikemori-Kawada, Megumi
    Minoshima, Yukinori
    Funahashi, Yasuhiro
    Matsui, Junji
    CANCER MEDICINE, 2018, 7 (06): : 2641 - 2653
  • [38] Preclinical mouse models of hepatocellular carcinoma: An overview and update
    Gu, Catherine Yujia
    Lee, Terence Kin Wah
    EXPERIMENTAL CELL RESEARCH, 2022, 412 (02)
  • [39] Experimental Models of Hepatocellular Carcinoma-A Preclinical Perspective
    Blidisel, Alexandru
    Marcovici, Iasmina
    Coricovac, Dorina
    Hut, Florin
    Dehelean, Cristina Adriana
    Cretu, Octavian Marius
    CANCERS, 2021, 13 (15)
  • [40] AZD6244 (ARRY-142886) Enhances the Antitumor Activity of Rapamycin in Mouse Models of Human Hepatocellular Carcinoma
    Huynh, Hung
    CANCER, 2010, 116 (05) : 1315 - 1325
12345